ACADIA Pharmaceuticals Inc.
ACAD
$20.86
$0.140.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 283.99M | 278.63M | 264.57M | 244.32M | 259.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 283.99M | 278.63M | 264.57M | 244.32M | 259.60M |
| Cost of Revenue | 110.98M | 109.48M | 98.69M | 98.66M | 122.53M |
| Gross Profit | 173.01M | 169.16M | 165.88M | 145.66M | 137.07M |
| SG&A Expenses | 155.62M | 133.40M | 133.51M | 126.37M | 130.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 266.60M | 242.88M | 232.19M | 225.03M | 252.61M |
| Operating Income | 17.39M | 35.76M | 32.37M | 19.29M | 6.99M |
| Income Before Tax | 26.32M | 44.60M | 40.21M | 27.78M | 161.09M |
| Income Tax Expenses | -247.25M | -27.18M | 13.55M | 8.79M | 17.34M |
| Earnings from Continuing Operations | 273.57M | 71.78M | 26.67M | 18.99M | 143.74M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 273.57M | 71.78M | 26.67M | 18.99M | 143.74M |
| EBIT | 17.39M | 35.76M | 32.37M | 19.29M | 6.99M |
| EBITDA | 20.32M | 38.71M | 35.31M | 22.24M | 12.20M |
| EPS Basic | 1.62 | 0.43 | 0.16 | 0.11 | 0.86 |
| Normalized Basic EPS | 0.10 | 0.17 | 0.15 | 0.10 | 0.05 |
| EPS Diluted | 1.60 | 0.42 | 0.16 | 0.11 | 0.86 |
| Normalized Diluted EPS | 0.10 | 0.16 | 0.15 | 0.10 | 0.05 |
| Average Basic Shares Outstanding | 169.34M | 168.84M | 167.83M | 166.81M | 166.54M |
| Average Diluted Shares Outstanding | 171.36M | 170.65M | 168.68M | 167.67M | 166.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |